Accord Healthcare Launches Fluorouracil in Australia

Accord Healthcare Launches Fluorouracil in Australia

Accord is pleased to announce that it has recently launched Fluorouracil in Australia.  This continues Accord’s growth in the oncology segment and provides valuable additional supply for the Australian market.  The following SKUs are now available via Symbion:

  • 1000mg/20mL

  • 2500mg/50mL

  • 5000mg/100mL

Accord Most Successful Company at Global Generics & Biosimilar Awards

We are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year.  Intas & Accord Healthcare also picked up the award for Company of the Year Asia-Pacific.

Accord Healthcare, Intas Pharmaceuticals and Lambda Research were honoured to be shortlisted in a record nine categories at The Global Generics & Biosimilars Awards 2018, which took place on Tuesday the 9th of October in Madrid, Spain.

The Global Generics & Biosimilars Awards reward ‘best practice’ in the two industries, while at the same time encouraging improvements in every aspect of the way business is conducted. Every award effectively underscores the efforts made by the global generics and biosimilars industries to make more affordable medicines available to more people everywhere.

We are truly proud of this success, particularly as it recognises the skill and dedication of the high performing teams throughout our company, and how they make us the award-winners we are today.

Accord Appoints National Sales Manager

Accord Healthcare is very happy to announce the appointment of Kareem Sourour in the role of National Sales Manager.  Kareem has almost 10 years’ experience in Pharma across both the hospital and retail markets and will take the lead in working with Accord’s partners in the Australian market to ensure their needs are met.  This is an important step in Accord’s continued growth into a strong and trusted partner in the Australian injectable generic market.  Kareem can be contacted on the details below:

kareem_sourour@accord-healthcare.com
National Sales Manager – Australia
Mobile Phone: 0412 946 665

 

Accord Recognised at Global Generics and Biosimilars Awards

Accord Recognised at Global Generics and Biosimilars Awards

Accord Healthcare was honoured to be shortlisted in several categories at The Global Generics & Biosimilars Awards, taking place on Tuesday the 23rd of October.

The awards are renowned for rewarding ‘best practice’ in the industry, while at the same time encouraging improvements in every aspect of the way business is conducted.  Every Award will effectively underscore the efforts made by the global generics and biosimilars industries to make more affordable medicines available to more people everywhere.

We are delighted to announce that Accord was the most successful company at the awards, winning awards for:

  • Patent Litigation of the Year,
  • Business Development of the Year, and
  • Acquisition of the Year

We are truly proud of this success, particularly as it recognises the skill and dedication of the high performing teams throughout our company, and how they make us the award-winners we are today.  Well done to all involved.

Accord Launches Azacitidine

Accord Launches Azacitidine

Accord Healthcare is pleased to announce the launch of Azacitidine Accord.  The product is now available via major wholesalers in all states and territories.  Contact us for further details.